Seraph

INVESTOR DEADLINE: Investors in Enochian Biosciences Inc. with Substantial Losses Have Opportunity to Lead Class Action Lawsuit – ENOB

Retrieved on: 
Saturday, August 6, 2022

The Enochian Biosciences class action lawsuit captioned Chow v. Enochian Biosciences Inc., No.

Key Points: 
  • The Enochian Biosciences class action lawsuit captioned Chow v. Enochian Biosciences Inc., No.
  • Enochian Biosciences and its top management have credited Serhat Gumrukcu (Gumrukcu), Enochian Biosciences co-founder, as the inventor of the technology and science behind Enochian Biosciences product pipeline.
  • A lead plaintiff acts on behalf of all other class members in directing the Enochian Biosciences class action lawsuit.
  • The lead plaintiff can select a law firm of its choice to litigate the Enochian Biosciences class action lawsuit.

ROSEN, A GLOBALLY RECOGNIZED LAW FIRM, Encourages Enochian BioSciences, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – ENOB

Retrieved on: 
Tuesday, August 2, 2022

WHAT TO DO NEXT: To join the Enochian BioSciences class action, go to https://rosenlegal.com/submit-form/?case_id=6517 or call Phillip Kim, Esq.

Key Points: 
  • WHAT TO DO NEXT: To join the Enochian BioSciences class action, go to https://rosenlegal.com/submit-form/?case_id=6517 or call Phillip Kim, Esq.
  • WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles.
  • The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.
  • 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017.

INVESTOR NOTICE: Enochian Biosciences Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - ENOB

Retrieved on: 
Tuesday, August 2, 2022

The Enochian Biosciences class action lawsuit captioned Chow v. Enochian Biosciences Inc., No.

Key Points: 
  • The Enochian Biosciences class action lawsuit captioned Chow v. Enochian Biosciences Inc., No.
  • Enochian Biosciences and its top management have credited Serhat Gumrukcu (Gumrukcu), Enochian Biosciences co-founder, as the inventor of the technology and science behind Enochian Biosciences product pipeline.
  • A lead plaintiff acts on behalf of all other class members in directing the Enochian Biosciences class action lawsuit.
  • The lead plaintiff can select a law firm of its choice to litigate the Enochian Biosciences class action lawsuit.

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Enochian Biosciences Inc. of Class Action Lawsuit and Upcoming Deadline – ENOB

Retrieved on: 
Monday, August 1, 2022

NEW YORK, Aug. 01, 2022 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Enochian Biosciences Inc. (Enochian or the Company) (NASDAQ: ENOB) and certain of its officers and directors.

Key Points: 
  • NEW YORK, Aug. 01, 2022 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Enochian Biosciences Inc. (Enochian or the Company) (NASDAQ: ENOB) and certain of its officers and directors.
  • To discuss this action, contact Robert S. Willoughby at [email protected] or 888.476.6529 (or 888.4-POMLAW), toll-free, Ext.
  • Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Enochian and Weber and Encourages Investors to Contact the Firm

Retrieved on: 
Monday, August 1, 2022

On May 25, 2022, the U.S. Department of Justice announced that Gumrukcu had been arrested and charged in a murder-for-hire conspiracy.

Key Points: 
  • On May 25, 2022, the U.S. Department of Justice announced that Gumrukcu had been arrested and charged in a murder-for-hire conspiracy.
  • On this news, Enochians stock price fell $2.17 per share, or 36.97%, to close at $3.70 per share on May 25, 2022.
  • Additionally, Weber announced that Chris Scherzinger is departing from his roles as Chief Executive Officer and director of the Company.
  • For more information on the Weber class action go to: https://bespc.com/cases/WEBR
    About Bragar Eagel & Squire, P.C.

EQUITY ALERT: Rosen Law Firm Encourages Enochian BioSciences, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action – ENOB

Retrieved on: 
Thursday, July 28, 2022

WHAT TO DO NEXT: To join the Enochian BioSciences class action, go to https://rosenlegal.com/submit-form/?case_id=6517 or call Phillip Kim, Esq.

Key Points: 
  • WHAT TO DO NEXT: To join the Enochian BioSciences class action, go to https://rosenlegal.com/submit-form/?case_id=6517 or call Phillip Kim, Esq.
  • The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.
  • Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company.
  • 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017.

ENOCHIAN ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Enochian Biosciences, Inc. and Encourages Investors to Contact the Firm

Retrieved on: 
Thursday, July 28, 2022

Investors have until September 26, 2022 to apply to the Court to be appointed as lead plaintiff in the lawsuit.

Key Points: 
  • Investors have until September 26, 2022 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
  • On May 25, 2022, the U.S. Department of Justice announced that Gumrukcu had been arrested and charged in a murder-for-hire conspiracy.
  • On this news, Enochians stock price fell $2.17 per share, or 36.97%, to close at $3.70 per share on May 25, 2022.
  • The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country.

INVESTOR ALERT: Enochian Biosciences Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - ENOB

Retrieved on: 
Wednesday, July 27, 2022

The Enochian Biosciences class action lawsuit captioned Chow v. Enochian Biosciences Inc., No.

Key Points: 
  • The Enochian Biosciences class action lawsuit captioned Chow v. Enochian Biosciences Inc., No.
  • A lead plaintiff acts on behalf of all other class members in directing the Enochian Biosciences class action lawsuit.
  • The lead plaintiff can select a law firm of its choice to litigate the Enochian Biosciences class action lawsuit.
  • An investors ability to share in any potential future recovery is not dependent upon serving as lead plaintiff of the Enochian Biosciences class action lawsuit.

Pomerantz Law Firm Announces the Filing of a Class Action Against Enochian Biosciences Inc. and Certain Officers and Directors – ENOB

Retrieved on: 
Tuesday, July 26, 2022

NEW YORK, July 26, 2022 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Enochian Biosciences Inc. (Enochian or the Company) (NASDAQ: ENOB) and certain of its officers and directors.

Key Points: 
  • NEW YORK, July 26, 2022 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Enochian Biosciences Inc. (Enochian or the Company) (NASDAQ: ENOB) and certain of its officers and directors.
  • To discuss this action, contact Robert S. Willoughby at [email protected] or 888.476.6529 (or 888.4-POMLAW), toll-free, Ext.
  • Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.

Xinhua Silk Road: Seraphim, Resolar sign MoU to deepen cooperation in EU market amid REPowerEU plan

Retrieved on: 
Thursday, July 21, 2022

Under the MoU, Seraphim will supply up to 1GW of PV modules to Resolar in 2023, which will be used in the latter's projects to be built in 2023.

Key Points: 
  • Under the MoU, Seraphim will supply up to 1GW of PV modules to Resolar in 2023, which will be used in the latter's projects to be built in 2023.
  • The MoU came under the European Union (EU)'s new REPowerEU plan, which was unveiled on March 8 to accelerate clean energy transition.
  • "Resolar regards Seraphim as a long-term partner," said Luis Lpez Martnez, CEO of Resolar, adding that he looks forward tofurther global collaboration with Seraphim.
  • It was created from the collaboration at the international level with more than 21 years' experience in solar energy.